

Talquetamab, a GPRC5D×CD3 bispecific antibody, in Chinese patients with relapsed/refractory multiple myeloma: efficacy and safety from the phase 1/2 MonumenTAL-1 study

Authors

Gang An,¹ Jie Jin,² Zhen Cai,² Hongmei Jing,³ Chengcheng Fu,⁴ Pengcheng He,⁵ Zhongjun Xia,⁶ Rui Liu,⁷ Liang Li,⁸ Xue Gai,⁷ Hong Zhang,⁷ Dian Zhu,⁸ Xinchao Luo,⁸ Binbin Sun,⁸ Hongmei Xu,⁸ Longen Zhou,⁸ Michela Campagna,⁹ Tara J. Masterson,¹⁰ Bonnie W. Lau,¹⁰ Thomas Renaud,¹¹ Christoph Heuck,¹⁰ Indrajeet Singh,¹⁰ Deeksha Vishwamitra¹⁰ and Luguì Qiu¹

¹National Clinical Research Center for Blood Diseases, State Key Laboratory of Blood Sciences, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China; ²First Affiliated Hospital, Zhejiang University College of Medicine, Hangzhou, Zhejiang, China; ³Peking University Third Hospital, Beijing, China; ⁴First Affiliated Hospital, Soochow University, Suzhou, China; ⁵First Affiliated Hospital, Xi'an Jiaotong University, Shaanxi, China; ⁶Sun Yat-sen

University Cancer Center, Guangzhou, China; ⁷Johnson & Johnson, Beijing, China; ⁸Johnson & Johnson, Shanghai, China; ⁹Johnson & Johnson, Madrid, Spain; ¹⁰Johnson & Johnson, Spring House, PA, USA and ¹¹Johnson & Johnson, Raritan, NJ, USA

Correspondence:

L. QIU - qiulg@ihcams.ac.cn

<https://doi.org/10.3324/haematol.2025.287334>

Received: May 1, 2025.

Accepted: October 1, 2025.

Early view: October 9, 2025.

©2026 Ferrata Storti Foundation

Published under a CC BY license 

Talquetamab, a GPRC5D×CD3 bispecific antibody, in Chinese patients with relapsed/refractory multiple myeloma: efficacy and safety from the phase 1/2

MonumenTAL-1 study

Supplemental materials

Supplementary figures

Figure S1. Mean (SD) talquetamab serum concentration-time profiles after SC administration of talquetamab at 0.01/0.06 mg/kg step-up doses followed by 0.4 mg/kg SC QW or 0.01/0.06/0.3 mg/kg step-up doses followed by 0.8 mg/kg SC Q2W.





Figure S2. sBCMA percentage change from baseline at C2D1 for responders versus non-responders in (A) the 0.4 mg/kg SC QW cohort and (B) the 0.8 mg/kg SC Q2W cohort.



C: cycle; D: day; Q2W: every other week; QW: weekly; sBCMA: soluble B-cell maturation antigen; SC: subcutaneous.